InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial

Rao, S., Sclafani, F., Eng, C., Guren, M. Gronlie, Adams, R. A. ORCID: https://orcid.org/0000-0003-3915-7243, Benson, A., Sebag-Montefiore, D., Segelov, E., Bryant, A., Peckitt, C., Roy, A., Seymour, M. T., Welch, J., Saunders, M. P., Muirhead, R., Bridgewater, J., Falk, S., Glynne-Jones, R., Arnold, D. and Cunningham, D. 2018. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018. Annals of Oncology. , vol.29 (Supple) Oxford University Press, VIII715-VIII716. 10.1093/annonc/mdy424.022

Full text not available from this repository.

Abstract

Whilst advanced squamous cell carcinoma of the anal canal (SCCA) is a rare disease incidence has risen by 2%/year for the past decade. There is no consensus on management of these pts who generally have a poor overall survival (OS) and to date no randomised trial has been completed. The combination of fluoropyrimidine /platinum agents is often considered standard 1st line therapy whilst taxanes have shown activity. We conducted a randomised phase II study to establish a standard of care.

Item Type:	Conference or Workshop Item (Paper)
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Oxford University Press
ISSN:	0923-7534
Last Modified:	09 Nov 2022 10:06
URI:	https://orca.cardiff.ac.uk/id/eprint/138303

Actions (repository staff only)

Edit Item